Welcome to our dedicated page for Alkermes Plc SEC filings (Ticker: ALKS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Alkermes plc (ALKS) SEC filings page on Stock Titan brings together the companys regulatory disclosures from the U.S. Securities and Exchange Commission, offering structured access to its Forms 8-K and other key documents. Alkermes is a global biopharmaceutical company focused on neuroscience, with commercial products for alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline that includes alixorexton, an investigational orexin 2 receptor agonist for narcolepsy and idiopathic hypersomnia.
Through its current reports on Form 8-K, Alkermes provides official details on material events. These include financial result announcements, where the company reports quarterly revenues, net income, EBITDA and adjusted EBITDA, along with updates to its annual financial expectations. Such filings often include reconciliations of non-GAAP measures like EBITDA and adjusted EBITDA and discuss revenue contributions from proprietary products and manufacturing and royalty arrangements.
Alkermes also uses Form 8-K to disclose clinical and regulatory milestones, such as positive topline results from phase 2 studies of alixorexton in narcolepsy type 1 and type 2, and to furnish related investor presentations. These documents help readers understand the design, endpoints and topline outcomes of the Vibrance studies and the companys plans for further development.
Another important category of filings relates to transaction agreements and financing. Alkermes has filed a transaction agreement and an amendment describing the terms under which it proposes to acquire Avadel Pharmaceuticals plc, including cash consideration per share and a non-transferable contingent value right linked to a potential regulatory milestone for LUMRYZ. The company has also filed an amended and restated bridge term loan credit agreement, outlining a senior secured bridge term loan facility intended to support financing of the proposed acquisition, along with associated covenants and security arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly identify items such as earnings updates, clinical trial disclosures, transaction terms and new financing commitments. Real-time updates from EDGAR allow investors to see new ALKS filings as they appear, while structured access to exhibits makes it easier to review detailed agreements, credit facilities and presentation materials.
For those tracking insider and governance information, Alkermes broader SEC reporting framework also encompasses ownership and compensation disclosures in its periodic and proxy filings, which can be accessed alongside 8-Ks. Together, these documents form a detailed record of Alkermes financial condition, strategic transactions, development progress and capital structure.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported option exercises and share sales in Alkermes ordinary shares. On February 2, 2026, he exercised an employee stock option for 5,000 shares at an exercise price of $19.34, converting it into ordinary shares. The filing shows two same-day sales of ordinary shares: 5,000 shares sold at a weighted average price of $34.2449 and 4,000 shares sold at $33.54. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the reported trades, Hopkinson directly owns 57,740 ordinary shares and holds 26,356 employee stock options that are fully vested in accordance with their terms.
Alkermes plc director Shane Cooke reported exercising employee stock options and selling the resulting shares. On 02/02/2026, he exercised 61,200 employee stock options at an exercise price of $31.64 per share as the options approached their 02/28/2026 expiration.
That same day, he sold 29,087 ordinary shares at a weighted average price of $34.3382 per share and 32,113 ordinary shares at a weighted average price of $34.7796 per share in multiple transactions. After these trades, Cooke directly owned 103,744 ordinary shares of Alkermes plc.
The filing notes that the exercise and sale of expiring options were executed under a Rule 10b5-1 trading plan adopted on 02/27/2025, and that the options were fully vested in accordance with their terms.
A holder of Alkermes plc ordinary shares has filed a Rule 144 notice to sell 61,200 shares. The shares are to be sold through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026 and an aggregate market value of $2,115,674.45.
The 61,200 ordinary shares were acquired on 02/02/2026 through the exercise of employee stock options in a broker-assisted cashless exercise. The filing notes that 165,117,509 ordinary shares were outstanding, providing context for the size of the planned sale.
Alkermes plc insider Craig Hopkinson has filed a notice to sell ordinary shares under Rule 144. The filing covers 9,000 ordinary shares to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $305,384.28 and 165,117,509 shares outstanding.
The shares come from a broker-assisted cashless exercise of 5,000 employee stock options on 02/02/2026 and vesting of restricted stock unit awards totaling 4,000 shares during February 2025. The form also lists several prior ordinary share sales by Hopkinson over the past three months with disclosed gross proceeds.
Alkermes plc filed a current report describing a new corporate presentation it will use at the J.P. Morgan Healthcare Conference. The presentation, furnished as Exhibit 99.1, includes the company’s estimated total revenues for the year ended December 31, 2025. These revenue figures are described as preliminary, unaudited and subject to change once Alkermes completes its review of its 2025 financial statements.
The company notes that the information in Items 2.02 and 7.01, and in Exhibit 99.1, is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities or automatically incorporated into other securities law filings unless specifically referenced.
Alkermes plc insider Craig Hopkinson has filed a Form 144 notice to sell ordinary shares. The filing covers 5,000 ordinary shares to be sold through Merrill Lynch on or about 01/08/2026 on NASDAQ, with an aggregate market value of $150,004.95. The filing notes 165,117,509 ordinary shares outstanding.
The 5,000 shares were acquired on 01/08/2025 through the exercise of employee stock options in a broker-assisted cashless exercise. The notice also lists prior sales over the past three months, including 9,000 ordinary shares sold on 10/15/2025 for gross proceeds of $283,776.70 and 9,000 shares sold on 11/03/2025 for $273,441.50, along with additional smaller transactions in December 2025 and early January 2026.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an options exercise and share sale. On 01/08/2026 he exercised an employee stock option for 5,000 ordinary shares at an exercise price of $19.34 per share and then sold 5,000 ordinary shares at a weighted average price of $30.001 per share, with individual sale prices ranging from $30.00 to $30.01.
Both the option exercise and the sale were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025, and the options exercised were fully vested in accordance with their terms. After these transactions, he directly owned 61,740 ordinary shares and 31,356 employee stock options.
Alkermes plc amended its agreement to acquire Avadel Pharmaceuticals, raising the cash offer from $18.50 to $21.00 per Avadel share, while keeping the potential additional $1.50 per share contingent value right unchanged. Alkermes also entered into an amended and restated senior secured bridge term loan facility of up to $1,512,562,923.28 to help fund the cash consideration and related fees and expenses for the Acquisition. The bridge loans, if drawn, will mature 364 days after funding and bear interest at either a Term SOFR-based rate plus 3.00% or an Alternate Base Rate plus 2.00%, with margin step-ups over time. Alkermes continues to expect completion of the Acquisition in the first quarter of 2026, subject to satisfaction or waiver of the stated conditions, and J.P. Morgan Securities LLC has confirmed sufficient resources are available to pay the cash consideration.
Alkermes plc reported positive topline results from Vibrance‑2, a randomized, double‑blind phase 2 study of alixorexton (formerly ALKS 2680) versus placebo in patients with narcolepsy type 2.
The company hosted an investor webcast and conference call to present the topline data, and furnished a press release as Exhibit 99.1 and an investor presentation as Exhibit 99.2. Information in Item 7.01 and Exhibit 99.1 is furnished and not deemed filed under the Exchange Act.
Alkermes plc (ALKS) reported an insider transaction by its EVP R&D and Chief Medical Officer, Craig C. Hopkinson. On 11/03/2025, he exercised 5,000 employee stock options at $19.34 and, on the same date, sold 9,000 ordinary shares at a weighted average price of $30.3824.
Both the option exercise and the sale were made under a Rule 10b5-1 trading plan adopted on 3/14/2025. The filing notes the sale occurred in multiple transactions at prices ranging from $30.34 to $30.56. Following these transactions, he directly beneficially owned 69,740 ordinary shares. He also reported 40,104 derivative securities (stock options) remaining. The options exercised were fully vested and carry an expiration date of 02/22/2031.